摘要
目的:分析人免疫球蛋白联合利巴韦林治疗重症腺病毒肺炎(SAP)患儿的效果。方法:选取2022—2023年该院治疗的60例SAP患儿进行前瞻性研究,按照随机数字表法将其分为研究组与对照组各30例。对照组使用利巴韦林治疗,研究组在对照组基础上联合人免疫球蛋白治疗,比较两组康复相关指标(退热时间、呼吸支持时间、肺啰音消失时间、住院时间)水平,治疗前后血气分析指标[氧合指数(OI)、动脉血氧分压(PaO_(2))、动脉血二氧化碳分压(PaCO_(2))]、T细胞亚群指标(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))、炎性因子[肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、降钙素原(PCT)、白细胞介素-6(IL-6)]水平,以及不良反应发生率。结果:研究组退热时间、呼吸支持时间、肺啰音消失时间、住院时间均短于对照组,差异有统计学意义(P<0.05);治疗后,两组OI、PaO_(2)水平均高于治疗前,且研究组高于对照组,两组PaCO_(2)水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05);治疗后,两组TNF-α、CRP、PCT、IL-6水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:人免疫球蛋白联合利巴韦林治疗SAP患儿可提高T细胞亚群指标水平,改善血气分析指标和康复相关指标水平,降低炎性因子水平,效果优于单纯利巴韦林治疗。
Objective:To analyze effects of human immunoglobulin combined with Ribavirin in treatment of children with severe adenovirus pneumonia(SAP).Methods:A prospective study was conducted on 60 children with SAP treated in this hospital from 2022 to 2023.According to the random number table method,they were divided into study group and control group,30 cases in each group.The control group was treated with Ribavirin,while the study group was treated with human immunoglobulin on the basis of that of the control group.The levels of rehabilitation-related indexes(antipyretic time,respiratory support time,lung rale disappearance time,hospitalization time),blood gas analysis indexes[oxygenation index(OI),arterial partial pressure of oxygen(PaO_(2)),arterial partial pressure of carbon dioxide(PaCO_(2))],T cell subsets(CD3^(+),CD4^(+),CD4^(+)/CD8^(+))and inflammatory factors[tumor necrosis factor-α(TNF-α),C-reactive protein(CRP),procalcitonin(PCT),interleukin-6(IL-6)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The antipyretic time,the respiratory support time,the lung rale disappearance time and the hospitalization time of the study group were shorter than those of the control group,the differences were statistically significant(P<0.05).After the treatment,the levels of OI and PaO_(2) in the two groups were higher than those before the treatment,and those in the study group were higher than those in the control group;the PaCO_(2) levels of the two groups were lower than those before the treatment,and that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).After the treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of TNF-α,CRP,PCT and IL-6 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Human immunoglobulin combined with Ribavirin in the treatment of the children with SAP can improve the levels of T cell subsets,improve the levels of blood gas analysis indexes and rehabilitation-related indexes,and reduce the levels of inflammatory factors.Moreover,it is superior to simple Ribavirin treatment.
作者
李丽丽
LI Lili(st Ward of Department of Pediatric Internal Medicine of Shangcai County People’s Hospital,Zhumadian 463800 Henan,China)
出处
《中国民康医学》
2025年第11期47-49,53,共4页
Medical Journal of Chinese People’s Health
关键词
儿童
重症腺病毒肺炎
人免疫球蛋白
利巴韦林
血气分析
T细胞亚群
炎性因子
Children
Severe adenovirus pneumonia
Human immunoglobulin
Ribavirin
Blood gas analysis
T cell subset
Inflammatory factor
